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Background: Obesity and weight gain are established risk factors for atrial fibrillation (AF). 
Whether body weight variability is also a risk factor for AF development is unclear. 
Methods: A nationwide population-based cohort of 8,091,401 adults from the Korean National 
Health Insurance Service database without previous history of AF and with at least 3 
measurements of body weight over a 5-year period were followed up for incident AF. Intra-
individual body weight variability was calculated using variability independent of mean, and 
high body weight variability was defined as the quartile with highest body weight variability 
(Q4) with Q1-3 as reference. 
Results: During a median of 8.1 years follow-up, AF was newly diagnosed in 158,347 
(2.0%). After adjustment for baseline body weight, height, age, sex, lifestyle factors and 
comorbidities, each increase of 1-SD in body weight variability was associated with a 5% 
increased risk of AF development, and the quartile with the highest body weight variability 
showed a 14% increased risk of AF development compared to the quartile with lowest body 
weight variability (HR 1.14, 95% CI 1.12-1.15). High body weight variability was significantly 
associated with AF development in all BMI groups except the very obese (BMI≥30), and this 
association was stronger in subjects with lower body weight. In underweight subjects, high 
body weight variability was associated with a 16% increased risk of AF development. High 
body weight variability was associated with a 7~12% increased risk of AF in all weight change 
groups. 
Conclusions: Body weight fluctuation was independently associated with an increased risk of 
AF development, especially in individuals with low body weight, and regardless of overall 
weight change. Avoiding substantial fluctuations in body weight may confer protection against 
the future risk of AF. 
  
Introduction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the general population1. Body 
weight and AF are closely related. Obesity is an established risk factor for AF, explaining 3.4% 
and 17.9% of all AF cases in Korea and US, respectively2, 3. In a meta-analysis, each 5-unit 
increase in body mass index (BMI) was associated with a 28% increase in the risk of incident 
AF, and different measures of adiposity were also associated with AF development4. On the 
other hand, underweight was also shown to increase the risk for incident AF5. AF patients with 
underweight had an increased risk of ischemic stroke and major bleeding, but direct oral 
anticoagulants showed better effectiveness and safety compared to warfarin as in patients with 
normal weight6, 7. Meanwhile, there is an ‘obesity paradox’ in patients with established AF, in 
which overweight and obese patients show lower all-cause mortality8.  
However, most studies are based on BMI measurements recorded at baseline and do not take 
into account body weight changes that occur throughout follow-up. Importantly, body-mass 
index (BMI) criteria developed by WHO may not be suitable for Asian populations, since such 
individuals have different associations between BMI, percentage of body fat, and health risks, 
from European populations [ref]. There is no recommendation, however, for new clear BMI 
cut-off points for all Asians; however, weight changes may be a simple and practical assessment 
in everyday practice. 
Indeed, some studies have shown that weight gain is associated with a higher risk of AF9, 10, 
and that interventions for weight loss can lower the risk of incident AF11 or AF burden12, 13. 
Individuals often oscillate in weight over time, and body weight fluctuation may also have 
negative consequences. Body weight variability is a risk factor for cardiovascular events and 
death in previous research14-16. Whether body weight fluctuation (rather than BMI variability 
[ref]) is also a risk factor for the development of AF is unclear. 
To address this, we aimed to find whether body weight fluctuation affects the development of 






This study utilized the database of National Health Insurance Service, a government 
corporation that provides health care benefits and regular health check-ups for the total Korean 
population, which can be used for population-based studies. Details of the database and health 
examinations are available in previous studies17, 18. Briefly, of 17,539,992 subjects (≥20 years) 
from the general population who underwent health examinations in 2009 to 2010 (year of 
health examination as index year), those who underwent at least 3 examinations during the 
previous 5 years (including the index year) were included (n=8,376,754). Of the remaining 
subjects, those with missing parameters (n=165,191), and those with the previous history of 
AF (n=120,162) were excluded. A total of 8,091,401 subjects were included in the final study 
population. The study population was followed from the index year until censoring by new-
onset AF, death, or until 31 December 2017 (end of study), whichever came first. This study 
was approved by the Institutional Review Board of Seoul National University Hospital [E-
1811-130-987], and informed consent was waived. 
 
Definition of body weight variability 
Intra-individual body weight variability can be measured by various indices, including standard 
deviation (SD), coefficient of variation (CV), average successive variability (ASV), and 
variability independent of the mean (VIM) (Supplementary Figure 2). A CV is calculated as 
the ratio of the SD to the mean. ASV is defined as the average absolute differences between 
successive body weight measurements and reflects the order of measurements. SD, CV or ASV 
are partially dependent on mean body weight level and its changes over time, and this may not 
be resolved even if adjusted for mean body weight. VIM is a measure of variability designed 
not to correlate with mean levels19, 20, and is calculated as 100 × SD/meanbeta, where beta is the 
regression coefficient based on the natural logarithm of the SD over the natural logarithm of 
the mean. VIM was used as the primary variability measure in this study. Subjects were 
classified into quartiles of body weight variability (Q1, lowest quartile; Q4, highest quartile). 
High body weight variability was defined as Q4 with reference body weight variability as Q1-
3; the rationale for this classification was that subjects in Q4 showed a steep increase in AF 
risk compared to those in the lower three quartiles (Q1-3) (Figure 1). 
Baseline body weight and characteristics were those collected in the index year. BMI was 
calculated as the weight in kilograms divided by the height in meters squared. Subjects were 
categorized into 5 groups according to BMI: underweight (BMI<18.5), normal weight (BMI 
18.5-22.9), overweight (BMI 23-24.9), obese stage I (BMI 25-29.9), and obese stage II 
(BMI≥30). The association between AF development and high body weight variability was 
compared within each BMI group. 
Overall body weight change was that between the first and last health exams; subjects were 
categorized according to total body weight change into 3 groups: weight loss (weight decrease 
of -5% or more), stable weight (weight change within 5%), and weight gain (weight increase 
of 5% or more), and the AF risk associated with high body weight variability was compared 
within each group. 
 
Definition of diseases 
Comorbidities and outcomes were defined using either diagnosis codes from the tenth revision 
of International Statistical Classification of Diseases and Related Health Problems (ICD-10) 
with healthcare usage and medication or health examination results, as in previous studies7, 21, 
22. The endpoint was incident nonvalvular AF (ICD-10 code I48, with ≥1 diagnosis during 
admission or at the outpatient clinic, with the exclusion of rheumatic mitral stenosis or 




The relation between body weight variability and risk of AF development was evaluated with 
body weight variability as a continuous variable and a categorical variable. Baseline 
characteristics are presented as mean ± SD for continuous variables and n (%) for categorical 
variables. The incidence rates of AF were calculated per 1,000 person-years. Cox proportional 
hazards regression was used to calculate unadjusted and adjusted hazard ratios (HR) and 95% 
CI values for the risk of developing AF. The proportional hazards assumption was evaluated 
graphically by the analysis using log-log plots, and there was no significant departure from 
proportionality in hazards over time. To control for confounding, we adjusted for baseline body 
weight, baseline height, age, sex, smoking, drinking, exercise, low income, diabetes mellitus, 
hypertension, dyslipidemia, and chronic kidney disease. Health examination results such as 
glucose, blood pressure, and creatinine clearance levels were not adjusted for due to collinearity 
with comorbidities. 
The risk of developing AF was calculated for each 1-SD increase and quartiles of body weight 
variability. Analyses were performed to assess the relationship between high body weight 
variability and AF risk based on baseline BMI categories and overall body weight change. 
Subgroup analyses for high body weight variability and AF risk were conducted for age strata, 
sex, and presence of comorbidities. Sensitivity analyses were performed using other indices of 
variability: SD, CV, and ASV. 
Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA), 




Characteristics of the study population 
A total of 8,091,401 subjects were followed up for a median of 8.1 years (mean 7.8±1.0 years), 
and 158,347 (2.0%) developed AF. Mean age was 48.1 years, and 58.7% were men. Mean 
baseline body weight was 64.4±11.5 kg. Body weight of each subject was measured 3 
(n=5,352,333; 66.2%), 4 (n=1,287,666; 15.9%), or 5 (n=1,451,402; 17.9%) times. Mean ASV 
was 2.2 kg, and mean VIM was 1.9%. The characteristics of the study population divided into 
quartiles of body weight variability by VIM are summarized in Table 1.  
Subjects with high body weight variability were younger, less likely to be male, less likely to 
exercise regularly, more likely to have a lower income, had a higher proportion of diabetes 
mellitus and heart failure, and a lower proportion of hypertension and dyslipidemia. P-values 
for trend were <0.001 for most variables because of the large study population, but there were 
little numerical differences among the groups for the rest of the variables. 
 
Body weight variability as a continuous variable and AF risk 
Risk of AF development increased significantly with each 1-SD increase in body weight 
variability (Table 2). Each 1-SD increase in body weight variability (VIM) was independently 
associated with a 5% increase in the risk of AF development (hazard ratio [HR] 1.049, 95% 
confidence interval [CI] 1.044-1.053).  
 
Quartiles of body weight variability and AF risk 
Incidence rates of AF were greatest in subjects with the highest quartile of body weight 
variability. Risk of AF development increased with each higher quartile of body weight 
variability after multivariable adjustment (Figure 1), significantly for Q3 and Q4 compared to 
Q1. There was a steep increase of AF risk in subjects in the highest quartile of body weight 
variability (Q4) compared to those in the lower three quartiles (Q1-3). Subjects in the highest 
quartile of body weight variability (VIM) showed a 14% increase in the risk of AF development 
compared to the lowest quartile (HR 1.14, 95% CI 1.12-1.15).  
 
Body weight variability and AF risk according to baseline body mass index 
While crude incidence rates increased with BMI, the risk of AF showed a J-shaped relationship 
with BMI in the fully adjusted model (Table 3). AF risk was lowest in the normal weight group, 
and there was a graded increase in AF risk with higher BMI in overweight and obese patients, 
while underweight subjects also showed an increased risk of AF. 
Subjects with high body weight variability (Q4) showed a shallow U-shaped relationship of 
BMI with AF incidence, with the highest incidence rate of AF in the underweight group (2.98 
per 100 person-years [PY], Figure 2A). On the other hand, subjects with reference body weight 
variability (Q1-3) showed a proportional increase of AF incidence with BMI, with the highest 
AF incidence in the obese group. After multivariable adjustment, high body weight variability 
was significantly associated with AF development in all BMI groups except for the extreme 
obese stage II group (BMI≥30). The association of high body weight variability with AF 
became stronger with lower BMI (p for interaction<0.001), and in underweight subjects, high 
body weight variability was associated with 16% increased risk of AF development (HR 1.16, 
95% CI 1.08-1.24). Obese subjects with high body weight variability showed lower crude AF 
incidence rates compared to those with reference variability, but after multivariable analysis, 
AF risk was increased (obese stage I) or comparable (obese stage II). 
 
Body weight variability and AF risk according to the overall weight change 
AF incidence was highest in subjects who lost the most weight, and lowest in those who gained 
the most weight between the first and last measurements (Table 3). In the fully adjusted model, 
overall weight change showed a reversed J-shaped relation with the risk of AF development; 
AF risk was highest in subjects with greatest overall weight loss, lowest in those who gained a 
small amount of weight (3-7%), and slightly increased in those with overall weight gain≥10%. 
Subjects with high body weight variability (Q4) showed higher AF incidence compared to 
those with lower variability in all weight change groups (Figure 2B). High body weight 
variability was independently associated with an elevated AF risk in all weight change groups, 
and this association became stronger with greater weight loss (p for interaction<0.001). 
Subjects with overall weight loss (≥-5%) and high body weight variability showed the highest 
AF incidence (3.57 per 100 PY) and AF risk (HR 1.12, 95% CI 1.09-1.15). 
 
Body weight variability and AF risk in subgroup analyses 
Incidence rates of AF were higher for subjects with high body weight variability in all 
subgroups by age strata, sex, and presence of comorbidities, except in the subgroup of young 
age adults (20-39 years). High body weight variability was consistently associated with AF 
development in subgroup analyses with multivariable adjustment as well, except for showing 
similar AF risk in the young age subgroup (Figure 3). This association was consistent in those 
with cardiac disease predisposing towards AF development such as heart failure or ischemic 




Sensitivity analyses with three other indices of variability, namely SD, CV, and ASV observed 
a consistent association between body weight variability and risk of AF development. Each 1-
SD increase in SD, CV, and ASV was independently associated with a 4.8%, 4.8% and 4.4% 
increase in incident AF risk, respectively (Table 2). The study population was divided into 
quartiles for each body weight variability index, and multivariable analysis showed that risk of 
AF incident increased in quartiles with higher body weight variability compared to Q1, 
significantly for Q3 and Q4 for all indices (Supplementary Table 2). There was a steep increase 
of AF risk for Q4 compared to the lower three quartiles (Q1-3), and subjects in Q4 showed 




In a large population-based cohort of more than 8 million Koreans, we found that (i) increasing 
body weight variability was independently associated with AF development; (ii) high body 
weight variability was significantly associated with AF development in all BMI groups except 
the very obese (BMI≥30), and this association was stronger in subjects with low body weight; 
(iii) high body weight variability was associated with an increased risk of AF regardless of the 
direction of overall weight change, though this association was stronger with weight loss; and  
(iv) underweight and obesity, weight loss and weight gain were all associated with AF 
development. 
 
Body weight variability, weight change, and AF risk 
Body weight influences the development of AF. Obesity is strongly associated with AF 
development2, 4, and increases the risk of AF independently of metabolic comorbidities; 
metabolically healthy obesity was associated with a 30% higher risk for AF21. Obesity causes 
arrhythmogenic remodeling of the atria related to the development and progression of AF23, 24. 
Meanwhile, being underweight was also associated with an excess risk of AF independent of 
thyroid disease, chronic lung disease, malignancy, or health-related behaviors5. 
Previous studies have shown that weight change affects AF development, but data on the effect 
of weight fluctuation on AF development are limited. Weight gain was demonstrated to be 
associated with an increased risk of AF in large prospective cohort studies9, 10. Weight loss may 
reverse AF risk associated with obesity according to data from the Women’s Health Study9. 
Also, weight reduction in obese subjects with bariatric surgery was associated with a lower risk 
of AF development11. In obese patients with established AF, intentional weight reduction by 
lifestyle intervention was associated with a reduced burden of AF12, 13. 
We found that body weight variability is an independent risk factor for new-onset AF. The risk 
associated with AF development increased steeply in the fourth quartile of body weight 
variability, conferring a 14% increased risk of AF compared to the lowest quartile. Each 1-SD 
increase in body weight variability was associated with a 5% increase in risk for incident AF. 
This association was valid in most subgroup analyses.  
Interestingly, the association between body weight variability and AF was especially stronger 
in subjects with low body weight. Incidence rates of AF were especially elevated in subjects 
with low BMI and high body weight variability; thus subjects with high body weight variability 
showed largely similar AF incidence rates regardless of BMI group, whereas subjects with 
reference body weight variability showed a proportional increase of AF incidence with BMI. 
The association between body weight variability and AF was attenuated with increasing BMI, 
becoming non-significant in the very obese (BMI≥30). We used VIM as the main measurement 
of body weight variability, which is designed to be uncorrelated to the mean levels and also 
adjusted for baseline body weight and height, so these findings are not driven by the lower 
baseline body weight. Subjects with lower BMI seem to be more vulnerable to fluctuations in 
body weight. This is supported by another study which found that BMI variability was 
associated with an increased risk of new-onset AF in underweight and normal weight 
individuals, but not in obese individuals (BMI≥25) in a much smaller cohort25.  The latter 
focused on BMI variability but given that BMI may be less suited for Asian subjects, the present 
analysis focuses on body weight variability.  Weight is more relevant to recent studies focused 
on weight reduction as an intervention to reduce AF burden or its complications [ref]. Such 
efforts are also important in optimizing outcomes after catheter ablation [ref]. 
In the present study, body weight variability was also associated with an increased risk of AF 
regardless of the direction of overall weight change. High body weight variability was 
associated with a 12% higher AF risk in subjects with weight loss or stable body weight, and 
7% higher AF risk in subjects with weight gain. This is in line with a previous study which 
found that weight fluctuation>5% attenuated the association between weight reduction and 
decreased AF burden in obese patients with AF13. While total weight change is important, 
weight fluctuation in the process is also an important factor to account for in the development 
of AF. 
Of interest was the finding that weight loss was associated with a greater increase in incident 
AF than weight gain. Weight gain of less than 10% did not increase AF risk; furthermore, 
weight gain of 3-7% was associated with the lowest AF risk, while weight gain of more than 
10% was associated with a 3% increase in AF development. Meanwhile, weight loss from small 
amounts was associated with a graded increase in AF risk, and weight loss of more than 10% 
was associated with a 34% increase in incident AF. This was an unexpected trend observed in 
a general population receiving health examinations, and we had no information on the reasons 
for weight loss. Similar findings have been found in the ARIC study, in which weight loss>5% 
was associated with a marked increase in incident AF10. This may be explained by the 
difference between intentional and unintentional weight loss. While intentional weight loss is 
associated with favorable outcomes regarding AF11-13, unintentional weight loss may be related 
to cachexia, decreased muscle mass, chronic diseases which can negatively affect AF 
development. 
 
Strengths and Limitations 
Strengths of this study include its large sample size of 8 million comprised from the whole 
Korean population who received health examinations, the long follow-up period of more than 
8 years, and completeness of data including all healthcare usage of subjects. Several limitations 
should also be considered. First, the diagnosis of AF was based on claims data. Therefore, AF 
events without healthcare usage may be undetected. Second, electrocardiograms or information 
on the duration of arrhythmic episodes were unavailable in the database, and we could not 
specify the types of AF. Third, the study population is subject to selection bias. Despite the fact 
that all Korean residents are entitled to health examinations by the government, only three-
fourths actually receive it because it is voluntary rather than obligatory. According to the 
Korean Statistical Information Service, 76.1% of total 17,633,406 subjects took the scheduled 
health examinations in 2015. Thus, the individuals in the present study may have healthier 
lifestyles and visit healthcare services more frequently than those who did not receive regular 
checkups. Fourth, we cannot exclude the presence of unadjusted confounding factors. Fifth, 
while this study found a statistically significant relationship between body weight variability 
and AF, there is insufficient evidence for a causal relationship. It needs to be tested in future 
prospective studies whether avoiding fluctuations in body weight is protective for AF. 
 
Conclusions 
Body weight variability was independently associated with an increased risk of AF 
development, especially in individuals with low body weight, and regardless of overall weight 
change. Avoiding substantial fluctuations in body weight may confer protection against future 
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Figure 1. Atrial fibrillation risk according to bodyweight variability (VIM) quartiles. 
Bar graphs represent incidence rates per 1000 person-years with scales on the left. Line graphs 
with error bars represent atrial fibrillation risk in hazard ratios with 95% confidence intervals 
with scales on the right.Hazard ratios were adjusted for baseline bodyweight, baseline height, 
age, sex, smoking, drinking, exercise, low income, diabetes mellitus, hypertension, 
dyslipidemia, and chronic kidney disease. 
VIM, variability independent of mean; Q, quartile. 
 
Figure 2. Bodyweight variability and atrial fibrillation risk as a function of (A) baseline 
body mass index and (B) overall bodyweight change. 
Bar graphs represent incidence rates per 1000 person-years with scales on the left. Line graphs 
with error bars represent atrial fibrillation risk in hazard ratios with 95% confidence intervals 
with scales on the right. Hazard ratios were adjusted for baseline bodyweight, baseline height, 
age, sex, smoking, drinking, exercise, low income, diabetes mellitus, hypertension, 
dyslipidemia, and chronic kidney disease. 
AF, atrial fibrillation; Q, quartile. 
 
Figure 3. Subgroup analysis for bodyweight variability and AF risk. 
Incidence rates per 100 person-years. HRs were adjusted for baseline bodyweight, baseline 
height, age, sex, smoking, drinking, exercise, low income, diabetes mellitus, hypertension, 
dyslipidemia, and chronic kidney disease. 
AF, atrial fibrillation; HR, hazard ratio; CI, confidence interval; Q, quartile. 
 
